tissue specific News
-
TISSIUM Selected for French Tech 120 Program
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has been named a French Tech 120 company for the 2021 program. French Tech 120 is a growth-stage program by La French Tech, built to provide government-backed support for the 120 fastest growing companies in France. This is the second year in a row that ...
By TISSIUM
-
Profacgen Updated Its E3 Ligase and Target Proteins Development Services
Profacgen has recently updated its E3 Ligase and Target Proteins Development Services, expanding the company’s portfolio of PROTAC development services. The updated services provide scientists with comprehensive advanced platform for their projects. The ubiquitin proteasome system relies heavily on E3 ligases (UPS). As a major modulator of protein homeostasis, UPS is essential in signal ...
By Profacgen
-
Adult Stem Cells
Adult stem cells are undifferentiated cells, found throughout the body after embryonic development, which multiply by cell division to replenish dying cells and regenerate damaged tissue. Adult stem cells support tissue and organ turnover throughout life by maintaining a delicate balance between apoptosis and tissue-specific cellular proliferation and differentiation. Adult stem cells reside ...
-
m5C Profiling Services Now Available by CD Genomics`s RNA Solutions Platform
RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The CD Genomics scientists are ready to help detect various types of RNA via meticulous and integrative approaches. These days, the product manager of CD Genomics announced the m5C profiling services to help researchers deeply ...
By CD Genomics
-
Cell Therapy Ltd Grants Japan License To Daiichi Sankyo for Its Heart Regeneration Medicine, Heartcel
Cell Therapy Ltd. (CTL) today announced the granting of the Japan license for its innovative cardiac regeneration medicine, Heartcel (immuno-modulatory progenitor [iMP] cells) to Daiichi Sankyo. Daiichi Sankyo will undertake all development, regulatory and commercial activities for iMP cells in the territory of Japan only, while CTL retains its worldwide rights outside of Japan as well as global ...
By Celixir plc
-
Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety
As a consulting and experimental service provider specializing in virology and microbiology, Creative Diagnostics recently introduced CC50/IC50 Assay service with a high level of assay sensitivity and accuracy. The CC50 and IC50 will be plotted using a sigmoidal dose-response curve, and the selectivity index (SI) for each compound is estimated by dividing the CC50 with the IC50. Pharmaceutical ...
-
Cancer Prevention and Early Detection Is One Step Closer as Universal DX Announces Breakthrough Study Results from Its Multi-omics + Computational Biology + Machine Learning Blood Tes
New results from the OMICS study, which will be presented atASCO, show Universal DX's blood test can detect colorectal cancer with extraordinary accuracy (92% sensitivity / 97% specificity), which exceeds currently available non-invasive tests for colorectal cancer screening Early detection cancer screening via a liquid biopsy is not only critical to save lives, but is a vast market opportunity, ...
-
Hockey For Heroes Renews Sponsorship with Celixir
Hockey for Heroes, a supporting charity of Help for Heroes who raise money to help our injured and fallen Heroes, today announces a multi-thousand pound sponsorship renewal with Celixir, a leading British Cell Therapy company. Celixir continues as the charity’s main shirt sponsor for 2018-19, enabling Hockey for Heroes to expand its program to enable injured veterans to take part in ...
By Celixir plc
-
TISSIUM Awarded 2.2M€ from i-Nov Competition to Address Chronic Rhinosinusitis
TISSIUM, a privately-owned life science company developing fullysynthetic, biomorphic programmable polymers, announced today it has been awarded 2.2M€ in financing that will accelerate its development of a drug-eluting tissue adhesive to address the unmet needs of Chronic Rhinosinusitis (CRS) patients. The funding comes from the Investments for the Future program (Programme ...
By TISSIUM
-
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ITM-31 is a carbonic anhydrase XII (CA XII)-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's ...
-
Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis
BOSTON – June 22, 2022 – Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a $27 Million Series B financing round. The round was led by an undisclosed strategic investor, with participation from Biovision Ventures, a new Europe-based fund, and existing investors, including MedTex ...
By Elucid
-
CD Genomics RNA Diversifies Its RNA Service Portfolio by Adding Whole Transcriptome Sequencing
RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The scientists at CD Genomics are ready to help detect various types of RNA via meticulous and integrative approaches. To further enrich its service types, the company recently announced to add Whole Transcriptome Sequencing to its ...
By CD Genomics
-
Startup Licenses UA-Invented Disruptive Biopsy Device
The University of Arizona has licensed the design for a next-generation needle biopsy instrument that utilizes electrosurgery and electrocautery to safely increase tissue sample volumes in minimally invasive biopsy procedures. The licensee is a startup company, Data Driven Diagnostics Sciences Inc., also known as D3Sciences, or D3S. The inventing team includes Dr. Michael Larson, resident ...
-
CD Formulation Empowers High-volume Manufacturing of Microspheres
Over the past decade, innovation in the field of microsphere production has reached new heights. Thanks to groundbreaking technology, CD Formulation has enabled mass production services for these versatile particles. Through a cutting-edge approach, CD Formulation is well-prepared to serve the industry by offering efficient and effective solutions for the mass fabrication of microspheres. From ...
-
New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens
Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor control Preclinical data also expand evidence on arenaviral immunotherapy targeting tumor self-antigens, reinforcing scientific approach for HB-300 program in prostate cancer Poster presentations at AACR underscore the versatility of ...
-
3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced the appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to its Board of Directors. Dr. Barer is the former CEO and Chairman of Celgene and currently serves as Chairman of Teva Pharmaceuticals. Dr. Slawin, Founder and Managing Partner of Rapha Capital Management, previously founded ...
-
Creative Proteomics's Targeted Metabolomic Platform Supports Ketone Body Detection
Creative Proteomics is an experienced outsourcing service provider offering professional and high-quality multi-omics services to academic research institutions and pharmaceutical industry. Creative Proteomics offers targeted metabolomics services for the enrichment and accurate quantitative profiling of a specific metabolite in blood, urine or other body fluids and tissues under specific ...
-
CD Bioparticles Announces New PLGA-Based Drug Delivery Systems for In Vitro and In Vivo Applications
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has recently launched its new line of PLGA-based drug delivery systems for in vitro and in vivo applications, including biocompatible and biodegradable PLGA nanoparticles with different surface modifications (e.g., COOH groups, methoxy PEG, and PEG-azide). In recent years, the development of nanotechnology ...
-
ASTM F755 - 99(2011) Standard Specification for Selection of Porous Polyethylene for Use in Surgical Implants
This specification covers the raw material and final product requirements, and the associated test methods for the selection of porous high density and ultra high molecular weight polyethylenes intended for use in surgical implants. The porous polyethylene may be used as a free standing product or as a coating on a substrate in nonloaded ...
-
EchoPixel’s True3D Receives Medical Device Registration in Japan
EchoPixel’s True3D software platform, a pre-operative planning technology that creates a hologram of the heart for study before an incision is ever made, has received PMDA Medical Device Registration and Approval in Japan. This first-of-its-kind software enables the entire heart surgical team to develop a precise personalized plan by interacting with specific organs and tissues as if ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you